NICE removes all caveats from final Xtandi recommendation
This article was originally published in Scrip
Executive Summary
NICE has issued final recommendation of Astellas' prostate cancer drug Xtandi (enzalutamide), removing the restriction that had been placed on the drug at the second draft stage which excluded patients who had been previously treated with Zytiga (abiraterone).